Biomolecular Effects of Jb1 (an IGF-I Peptide Analog) in a Rat Model of Oxygen-Induced Retinopathy

被引：14

作者：

Brock, Romy S.

Gebrekristos, Bisrat H. ^{[2
]}

Kuniyoshi, Katherine M. ^{[2
]}

Modanlou, Houchang D.

Falcao, Mario Cicero ^{[3
]}

Beharry, Kay D. ^{[1
]}

机构：

[1] Univ Calif Irvine, Div Neonatol, Dept Pediat, Orange, CA 92868 USA

[2] Miller Childrens Hosp, Dept Pediat, Long Beach, CA 90806 USA

[3] Univ Sao Paolo, Dept Pediat, BR-03071000 Sao Paulo, Brazil

来源：

PEDIATRIC RESEARCH | 2011年 / 69卷 / 02期

关键词：

GROWTH-FACTOR-I; RETINAL NEOVASCULARIZATION; NEONATAL-RAT; VEGF; INHIBITION; BIRTH; PREMATURITY; RECEPTOR; HYPOXIA; HYPEROXIA;

D O I：

10.1203/PDR.0b013e318204e6fa

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Low-serum IGF-I levels at birth is a risk factor for the development of retinopathy of prematurity in extremely LBW infants. We tested the hypothesis that JB1 (an IGF-I analog) prevents oxygen-induced retinopathy in our rat model. Neonatal rats were exposed to 50% oxygen with brief, clustered, hypoxic (12%) episodes from birth to P14. The pups were treated with s.c. injections of 1) JB1 (1 mu g/d) on P1, P2, and P3 (JB1x3); 2) JB1 (1 mu g/d) on alternate days from P1 to P13 (JB1x7); or 3) equivalent volume saline. Control littermates were raised in room air (RA) with all conditions identical except for inspired O-2. Groups were analyzed after hyperoxia/hypoxia (H/H) cycling at P14 or allowed to recover in RA until P21. Systemic and ocular VEGF, soluble VEGFR-1, and IGF-I; retinal vasculature; and gene profile of retinal angiogenesis were assessed. JB1x3 was more effective with associated increases in sVEGFR-1 and decreased retinal pathologies than JB1x7. We conclude that early short-term exposure to systemic JB1 treatment normalizes retinal abnormalities seen with H/H cycling, an effect that may involve sVEGFR-1. (Pediatr Res 69: 135-141, 2011)

引用

页码：135 / 141

页数：7

共 22 条

[1] SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].